In a research report issued Tuesday, Oppenheimer analyst Christopher Marai reiterated an Outperform rating on Prosensa Holding (NASDAQ:RNA) with a price target of $25, following …
In a research report issued Tuesday, Oppenheimer analyst Christopher Marai maintained an Outperform rating on PTC Therapeutics (NASDAQ:PTCT) with a $60 price target, as …
In a research report issued Tuesday, Oppenheimer analyst Christopher Marai maintained an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $45 price target, as longer …
In a research report released Tuesday, Oppenheimer analyst Bret Jones maintained an Underperform rating on Athenahealth (NASDAQ:ATHN) with a $90 price target, as the company …
In a research report issued today, Oppenheimer analyst Akiva Felt initiated coverage with an Outperform rating on Foamix Pharmaceuticals (NASDAQ:FOMX) and a $15 price target, which represents …
In a research note released Monday, Oppenheimer analyst Glenn Greene maintained a Perform rating on Infosys (NYSE:INFY), as the company reported 2Q:FY15 results with revenue increasing 3.1% Q/Q …
In a research report issued today, Oppenheimer analyst Rohit Vanjani maintained an Outperform rating on Lannett Company (NYSE:LCI) and slightly raised his price …
In a research report issued today, Oppenheimer analyst Jim Giannakouros upgraded shares of Graco (NYSE:GGG) to Outperform rating and raised his price target to …
In a research report published today, Oppenheimer analyst Ian Zaffino reiterated an Outperform rating on Gencorp (NYSE:GY) with a $20 price target, following the company’s third …
In a research report issued today, Oppenheimer analyst Yigal Nochomovitz maintained a Perform rating on Vertex Pharmaceuticals (NASDAQ:VRTX), while no price target was provided. Nochomovitz …
